


| OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars |
|
* Potential first-in-class treatment for hypertrophic scars with no FDA-approved medicines to to-date * Phase 2a trial follows the successful completion of OliX’s Phase 1 trial in the U.K. in November 2019 * OliX retains global rights to develop and commercialize OLX10010 outside Asia SUWON, Republic of Korea, Oct.
Posted: 2020-10-30 15:23:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.